|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600120248 |
|
最近更新日期: Date of Last Refreshed on: |
2026-03-11 11:01:30 |
|
注册时间: Date of Registration: |
2026-03-11 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
补充磷虾油对高胆固醇血症的改善效果-一项随机对照试验 |
|
Public title: |
Effects of krill oil supplementation on hypercholesterolemia: a randomized controlled trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
补充磷虾油对高胆固醇血症的改善效果-一项随机对照试验 |
|
Scientific title: |
Effects of krill oil supplementation on hypercholesterolemia: a randomized controlled trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陈妍芳 |
研究负责人: |
郭晓飞 |
|
Applicant: |
Yanfang Chen |
Study leader: |
Xiaofei Guo |
|
申请注册联系人电话: Applicant telephone: |
+86 198 6220 2128 |
研究负责人电话:
Study leader's |
+86 181 0639 0969 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
yfchen0316@163.com |
研究负责人电子邮件: Study leader's E-mail: |
guoxf@qdu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
山东省青岛市市北区登州路38号 |
研究负责人通讯地址: |
山东省青岛市市北区登州路38号 |
|
Applicant address: |
No.38 Dengzhou Road, Shibei District, Qingdao City, Shandong Province, China |
Study leader's address: |
No.38 Dengzhou Road, Shibei District, Qingdao City, Shandong Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
青岛大学公共卫生学院 |
||
|
Applicant's institution: |
School of Public Health, Qingdao University |
||
|
研究负责人所在单位: |
青岛大学公共卫生学院 |
||
|
Affiliation of the Leader: |
School of Public Health, Qingdao University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
QDU-HEC-2026002 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
青岛大学青岛医学院伦理委员会 |
||
|
Name of the ethic committee: |
Approval document of Ethics Committee Medical College of Qingdao University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-01-06 00:00:00 | ||
|
伦理委员会联系人: |
刘海伦 |
||
|
Contact Name of the ethic committee: |
Hailun Liu |
||
|
伦理委员会联系地址: |
山东省青岛市宁夏路38号 |
||
|
Contact Address of the ethic committee: |
308 Ningxia Road, Qingdao, Shandong, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 532 8299 1029 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
青岛大学 |
||||||||||||||||||||||
|
Primary sponsor: |
Qingdao University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
山东省青岛市市北区登州路38号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.38 Dengzhou Road, Shibei District, Qingdao City, Shandong Province, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
挪威阿克海洋生物公司提供干预物,其余经费自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Aker BioMarine provides intervention materials, and the remaining funds are self funded |
||||||||||||||||||||||
|
研究疾病: |
高胆固醇血症 |
||||||||||||||||||||||
|
Target disease: |
Hypercholesterolemia |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
1.通过随机双盲平行对照试验,探究膳食补充磷虾油干预对胆固醇、脂蛋白等临床参数的影响; 2.通过代谢组学技术,筛选磷虾油干预前后显著差异的内源性代谢物,识别潜在生物标志物; 3.基于 KEGG 通路富集分析,阐明磷虾油调控的关键代谢通路与作用靶点,多维视角揭示磷虾油干预改善高胆固醇血症的机制,为其在心血管疾病预防与干预中的应用提供科学依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. To investigate the effects of dietary krill oil supplementation on clinical parameters—including cholesterol and lipoprotein profiles—through a randomized, double-blind, parallel-group, placebo-controlled trial; 2. To apply metabolomics approaches to identify significantly altered endogenous metabolites before and after krill oil intervention and to discover potential biomarkers associated with its biological effects; 3. To elucidate the key metabolic pathways and molecular targets modulated by krill oil via KEGG pathway enrichment analysis, thereby providing a multi-dimensional mechanistic understanding of how krill oil ameliorates hypercholesterolemia and offering scientific evidence to support its application in the prevention and management of cardiovascular diseases. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄在35-65周岁,性别、民族不限; 2.被诊断为高胆固醇血症,TC≥5.2 mmol/L或LDL-C≥3.4 mmol/L; 3.每周海鲜摄入量不超过200g;或近3个月未服用过n-3多不饱和脂肪酸补充剂; 4.自愿参加并签订知情同意书,配合完成研究者安排的问卷或接受电话随访。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Age between 35-65 years old, regardless of gender or ethnicity; 2. Diagnosed with hypercholesterolemia, TC >= 5.2 mmol/L or LDL-C >= 3.4 mmol/L; 3. Weekly seafood intake should not exceed 200g; or have not taken n-3 polyunsaturated fatty acid supplements in the past 3 months; 4. Voluntarily participate and sign an informed consent form, cooperate to complete the questionnaire arranged by the researcher or accept telephone follow-up. |
||||||||||||||||||||||
|
排除标准: |
1.家族性高脂血症或甘油三酯浓度>4.56mmol/L; 2.患有任何形式的肝、肾及恶性肿瘤等疾病; 3.已知对海鲜或研究药物(n-3多不饱和脂肪酸)过敏者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Familial hyperlipidemia or triglyceride concentration >4.56mmol/L; 2. Suffering from any form of liver, kidney, and malignant tumors; 3. Individuals known to be allergic to seafood or research drugs (n-3 polyunsaturated fatty acids). |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-04-01 00:00:00至 To 2026-09-02 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-04-01 00:00:00 至 To 2026-04-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由研究负责人将研究对象编号,利用Stata进行区组随机分配,使年龄、性别和BMI分配均匀。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The study subjects were numbered by the study leader and randomly assigned by block using Stata, so that age, sex and BMI were evenly distributed. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
在整个研究过程中,负责数据收集和结局评估的研究人员以及受试者本人均不知晓具体的分组情况 |
|
Blinding: |
Throughout the entire research process, the researchers responsible for data collection and outcome evaluation, as well as the participants themselves, were unaware of the specific grouping situation. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
原始数据不共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The original data cannot be shared. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
原始记录保存于纸质版并拍照记录整理于相册,电子数据由EXCEL管理并备份。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The original records are saved in paper format and photographed and organized in an album. The electronic data is managed and backed up by EXCEL. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |